Although these three studies had the inherent limitation of retrospective design, they demonstrated the real-world safety and efficacy of ivosidenib in IDH-mutant glioma and deepened our understanding of which patients may or may not respond to IDH inhibitors. This evidence concerns the gene IDH1 and central nervous system cancer.